Health
Sharp Increase in Lassa Fever Reported in Week 51 of 2023 – NCDC

The Nigerian Centre for Disease Control (NCDC), has reported a sharp increase in Lassa Fever cases in week 51 of 2023.
The centre, however, reported a lower fatality rate compared to the same period the previous year.
The information was released in NCDC’s official website on Sunday in Abuja.
The centre said that in week 51 of 2023, the number of newly confirmed lassa fever cases increased significantly from10 in week 50, to 26 cases.
“These cases were reported in Bauchi, Ondo, Taraba and Plateau States,” it said.
“Cummulatively, from week 1 to week 51 of 2023, a total of 215 deaths have been reported, resulting in a case fatality rate of 17.
5 per cent.“This figure is slightly lower than the record for the same period in 2022, which was 17.9 per cent.
“Throughout the year 2023, Lassa fever cases was reported in 28 states across 121 Local Government Areas.
“The majority of confirmed cases, accounting for 77 per cent, were reported in Ondo, Edo, and Bauchi States.
“Specifically, Ondo State reported 35 per cent of the confirmed cases, Edo reported 28 per cent and Bauchi reported 14 per cent,” it stated.
The agency said that the age group most affected by Lassa fever was 21-30 years, with cases ranging from 1 to 93 years.
“It said that the median age of confirmed cases was 32 years.
The male-to-female ratio for confirmed cases is 1 and 0.9,” it stated.
The centre said that the number of suspected cases has increased compared to the same period in 2022.
It said that additionally, two healthcare workers were affected in week 51.
To address the situation, multi-sectoral Public Health Emergency Operation Centres (PHEOC) have been activated at the national level and in the affected states, it said.
It said that challenges faced in combating Lassa fever included the late presentation of cases, leading to an increase in the case fatality rate.
“Poor health-seeking behaviour is also observed due to the high cost of treatment and clinical management of the disease.
“Poor environmental sanitation conditions and low awareness are also observed in high-burden communities,” it stated.
It said that the report was based on case-based data retrieved from the National Lassa fever Emergency Operations Centre.
The statement identified symptoms of the disease to include fever, headache, sore throat, cough, nausea, vomiting, diarrhoea, myalgia and chest pain.
Other symptoms include unexplained bleeding/haemorrhage, it said. (NAN)
Health
Nigeria Requires N2.2trn to Eliminate Cervical Cancer by 2030 – Prof. Adewole

Prof. Isaac Adewole, Chairman of the National Task Force on Cervical Cancer Elimination (NTF-CCE), says Nigeria will require N2.2 trillion to implement comprehensive cervical cancer interventions between 2026 and 2030.
Adewole, a former Minister of Health, made this known on Tuesday in Abuja during the launch of the Partnership to Eliminate Cervical Cancer in Nigeria (PECCiN), an initiative of the NTF-CCE.
The initiative, launched at the State House by the First Lady, Sen.
Oluremi Tinubu, aims to accelerate Nigeria’s achievement of the World Health Organisation’s (WHO) 90-70-90 targets for cervical cancer elimination.reports that PECCiN seeks to catalyze multi-sectoral efforts to prevent, screen, and treat cervical cancer through sustained coordination, resource mobilization, and scale-up of service delivery.
According to Adewole, the interventions are grouped into three categories: primary prevention, secondary prevention, and tertiary treatment.
He explained that the Human Papilloma Virus (HPV) vaccination programme will be delivered through fixed sessions at health facilities and outreach-based immunisation campaigns.
“The total direct implementation cost over the five years is estimated at N387.52 billion,” he said.
“Including administrative and supervisory costs, the total cost of HPV vaccination will amount to N426.28 billion.”
He said cervical cancer screening over the same period is estimated to cost N351 billion, targeting 14.4 million women.
On tertiary treatment, Adewole noted that nearly 300,000 women will require care for invasive cervical cancer between 2026 and 2030.
“The country is projected to spend approximately N1.42 trillion on treatment, with the cost per patient dropping from N8.7 million in 2026 to N4.1 million by 2030,” he added.
In spite of other competing priorities, he urged investment in cervical cancer elimination due to its high return on investment.
“We seek your commitment and support to implement robust cervical cancer elimination interventions in Nigeria.
“This will ensure that every woman is financially protected throughout her life and no eligible adolescent is left behind in HPV vaccination.”
Dr Muyi Aina, Executive Director of the National Primary Health Care Development Agency (NPHCDA), said the Federal Government launched the HPV vaccine campaign on Oct. 24, 2023, targeting girls aged 9 to 14.
He announced that 14 million girls had already received the vaccine.
“This milestone is unprecedented globally and was achieved through strong leadership from President Bola Tinubu, the support of the First Lady, and collaboration across ministries and communities.
“The media also played a key role in spreading awareness and engaging civil society.”
Aina reaffirmed the agency’s commitment to sustaining the programme, stating that the HPV vaccine has been incorporated into the routine immunisation schedule and that primary healthcare centres are being revitalised to support service delivery.
Prof. Usman Aliyu, Director-General of the National Institute for Cancer Research and Treatment (NICRAT), described cervical cancer as a serious burden affecting mothers, sisters, caregivers, and peers across communities.
He said the growing burden prompted the development of the National Strategic Plan for the Prevention and Control of Cervical Cancer (2023–2037).
“This plan, reflecting best practices and local realities, serves as our national roadmap for cervical cancer elimination,” he said.
Aliyu added that NICRAT has constituted a national taskforce comprising experts and stakeholders to drive implementation.
He also highlighted efforts to promote innovative research, harmonise treatment protocols, and expand culturally sensitive awareness and screening campaigns.
The event featured the presentation of the National Cervical Cancer Elimination Plan and the unveiling of the PECCiN partnership logo. (NAN)
Health
Otu’s Wife Champions Healthcare Access for 500 Elderly Citizens

The Wife of the Cross River Governor, Mrs Eyoanwan Otu, has sponsored the enrollment of 500 senior citizens, aged 70 and above, into the Cross River Health Insurance Scheme.
The gesture, which covers the premiums of the elderly citizens for two years, targeted the vulnerable senior citizens in the 18 Local Government Areas of the state.
The Director General of the agency, Mr Godwin Iyala, described the initiative as “a significant milestone in the first lady’s humanitarian outreach”.
According to Iyala, the first lady had already made full financial commitment to cover the 500 beneficiaries for the next two years.
“This initiative prioritises our elderly population, many of whom had spent decades serving their families and communities.
“Her Excellency has once again demonstrated her deep sense of empathy and leadership.
“The ripple effect of this act is far-reaching because when the aged are cared for, families are relieved, and the moral fabric of our society is strengthened,” he said.
He commended Otu for the initiative, describing it as a lifeline for elderly citizens, particularly those in the rural areas, who face significant barriers in accessing healthcare.
Iyala stated that the Agency would begin immediate enrollment of the beneficiaries into the health insurance database, to ensure they begin to enjoy prompt and uninterrupted access to medical services.
He further said that the initiative was expected to significantly ease the burden of healthcare cost to elderly citizens, offering them a renewed sense of dignity and security in their twilight years. (NAN)
Health
WHO Approves 2 New Vaccines to Protect Infants From RSV

The World Health Organization (WHO), on Friday, issued recommendations for two new immunisation tools to protect infants from Respiratory Syncytial Virus (RSV)They included a maternal vaccine, administered to pregnant women in their third trimester to protect their newborns.The other was a long-acting antibody injection for infants, which begins to protect within a week of administration and lasts for at least five months.
According to WHO, RSV is the leading cause of acute lower respiratory infections in children globally. It causes around 100,000 deaths and 3.6 million hospitalisations each year among children under the age of five, while infants under six months are most at risk.Alarmingly, 97 per cent of these deaths occur in low and middle-income countries, according to WHO.Although RSV can infect people of all ages, “it is especially harmful to infants, particularly those born prematurely,” a WHO official, Kate O’Brien, said.O’Brien added that around half of all RSV-related deaths occurred in babies younger than six months.Considering the global burden of severe RSV illness in infants, WHO recommended that all countries adopt either the maternal vaccine or the antibody injection as part of their national immunisation strategies.“These RSV immunisation products can transform the fight against severe RSV disease, dramatically reduce hospitalisations and deaths, and ultimately save many infant lives worldwide,” O’Brien said. (NAN)